REG - PureTech Health PLC - Directorate Change

Puretech HealthAnnouncement

08/07/2025 17:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250708:nRSH2506Qa&default-theme=true

RNS Number : 2506Q  PureTech Health PLC  08 July 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART
OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED

 

8 July 2025

PureTech Health plc

 

PureTech Announces Board Change

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company
dedicated to changing the lives of patients with devastating diseases, today
announces that Raju Kucherlapati, PhD, has stepped down from his role as a
member and Chair of the Board of Directors.

 

"Raju has been an integral part of PureTech's journey for almost two decades,
and we are deeply grateful for his dedication and leadership," said Bharatt
Chowrira, PhD, JD, PureTech's Chief Executive Officer. "On behalf of the
board, I'd like to wish Raju all the best in his future endeavors."

 

PureTech has appointed Sharon Barber-Lui, PureTech's Audit Committee Chair, as
Interim Chair of the Board of Directors. In collaboration with the Nominating
Committee, Ms. Barber-Lui will lead the process to identify a new Chair of the
Board of Directors and will engage with shareholders to gather input on the
criteria and overall board evolution as part of the process.

 

Robert Langer, ScD, PureTech's Co-founder and member of the board said, "Raju
is a unique individual, an amazing scientist, and a great friend and mentor to
so many people in the biotech industry. It has been an honor and a privilege
to serve alongside Raju for so many years at PureTech. I speak for the entire
board in thanking him for his many years of dedication and his outstanding
contributions."

 

During his tenure on the board, Dr. Kucherlapati helped guide PureTech from
its startup phase into an established biotherapeutics company, which has an
industry-leading track record of advancing breakthrough medicines, such as the
recently FDA-approved Cobenfy™, and launching innovative Founded Entities,
most recently, Seaport Therapeutics.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep portfolio through its
experienced research and development team and its extensive network of
scientists, clinicians, and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including three that have been approved by the U.S. Food and Drug
Administration. A number of these programs are being advanced by PureTech or
its Founded Entities in various indications and stages of clinical
development, including registration-enabling studies. All of the underlying
programs and platforms that resulted in this portfolio of therapeutic
candidates were initially identified or discovered and then advanced by
the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation statements that relate to our expectations around
our therapeutic candidates and approach towards addressing major diseases, our
intention to initiate a process to identify a new Chair of the Board of
Directors, our future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and are subject
to known and unknown risks, uncertainties and other important factors that
could cause actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those risks,
uncertainties and other important factors described under the caption "Risk
Factors" in our Annual Report on Form 20-F for the year ended December 31,
2024 filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only as at the
date of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information, future
events or otherwise.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADZGGNVRMGKZM